Article
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Dec 2011
Lai Albert, Kharbanda Samir, Pope Whitney B, Tran Anh, Solis Orestes E, Peale Franklin, Forrest William F, Pujara Kanan, Carrillo Jose A, Pandita Ajay, Ellingson Benjamin M, Bowers Chauncey W, Soriano Robert H, Schmidt Nils O, Mohan Sankar, Yong William H, Seshagiri Somasekar, Modrusan Zora, Jiang Zhaoshi, Aldape Kenneth D, Mischel Paul S, Liau Linda M, Escovedo Cameron J, Chen Weidong, Nghiemphu Phioanh Leia, James C David, Prados Michael D, Westphal Manfred, Lamszus Katrin, Cloughesy Timothy, Phillips Heidi S
Abstract excerpt
PURPOSE: Mutation in isocitrate dehydrogenase 1 (IDH1) at R132 (IDH1(R132MUT)) is frequent in low-grade diffuse gliomas and, within glioblastoma (GBM), has been proposed as a marker for GBMs that arise by transformation from lower-grade gliomas, regardless of clinical history. To determine how GBMs arising with IDH1(R132MUT) differ from other GBMs, we undertook a comprehensive comparison of patients presenting...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
